BOULDER, Colo., May 31 /PRNewswire-FirstCall/ -- Pharmion Corporation today announced that the Company will host an Investor and Analyst Event on Monday, June 4 at 6:00-7:30pm Central time during the ASCO 43rd Annual Meeting in Chicago.
The meeting will provide investors and analysts with the insights and perspectives of U.S. and European physicians regarding Pharmion's commercial and pipeline products. Members of the Pharmion management team will also be available to discuss corporate activities.
The event will be webcast live and will be accessible via the Pharmion website at http://www.pharmion.com.
Contact Details: Breanna Burkart/Anna Sussman Directors, Investor Relations and Corporate Communications Pharmion Corporation +1 720-564-9150
About Pharmion
Pharmion is a biopharmaceutical company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www.pharmion.com.
Pharmion CorporationCONTACT: Breanna Burkart or Anna Sussman, Directors, Investor Relationsand Corporate Communications of Pharmion Corporation, +1-720-564-9150
Web site: http://www.pharmion.com/
